Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Our technology harnesses the power and synergy of nanotechnology, biologics and small molecules. Mersana is advancing its own pipeline of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications. Utilizing our technology, we are developing a portfolio of next-generation antibody-drug conjugates (ADC) with superior properties not found with current ADC technologies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/18/12 | $10,000,000 | |||
| 07/31/12 | $27,000,000 | Series A-1 |
Harris & Harris Group Pfizer Venture Investments Rho Ventures | undisclosed |
| 03/02/15 | $35,000,000 | Series B-1 |
Elliott Sigal Pfizer Venture Investments Rock Springs Capital | undisclosed |
| 06/16/16 | $33,000,000 | Series C |
Arrowpoint Partners Cormorant Asset Management Takeda Pharmaceutical Company Wellington Management Company | undisclosed |
